Figure 4.
IGA mod 2011 0/1 and PASI responses up to Week 52 (NRI with extended analysis visit window at Week 12). ETN, etanercept; HD, high dose; IGA mod 2011, Investigator’s Global Assessment Modified 2011; LD, low dose; NRI, non‐responder imputation; PASI, Psoriasis Area and Severity Index; PBO, placebo; SEC, secukinumab.